Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor

Experimental Hematology

Volumn 30, Issue 9, 2002, Pages 1001-1009

  Rameshwar, Pranela ^a   Gascon, Pedro ^a   Oh, Hyun S ^a,b   Denny, Thomas N ^a   Zhu, Goafa ^a   Ganea, Doina ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Wonkwang Health Science University   (South Korea)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; NYLON; PROTEIN VPAC1; RECEPTOR; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BONE MARROW CELL; CELL ASSAY; CELL PROLIFERATION; CELLULAR PARAMETERS; CLONOGENIC ASSAY; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; DOSE RESPONSE; ERYTHROID CELL; GRANULOCYTE; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; STROMA;

ADULT; BONE MARROW CELLS; CELL DIVISION; CELL LINE; COCULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; CROSS-LINKING REAGENTS; ERYTHROID PROGENITOR CELLS; ERYTHROPOIETIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; INTERLEUKIN-3; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0036754122     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00875-5     Document Type: Article

References (53)

1. Krause D.S., Theise N.D., Collector M.I.et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 105:2001;369.
2. Devine S.M., Peter S., Martin B.J., Barry F., McIntosh K.R. Mesenchymal stem cells. Stealth and suppression Cancer J. 7:2001;S76.
3. Afan A.M., Broome C.S., Nicholls S.E., Whetton A.D., Miyan J.A. Bone marrow innervation regulates cellular retention in the murine haemopoietic system. Br J Haematol. 98:1997;569.
4. Rameshwar P. Substance P. A regulatory neuropeptide for hematopoiesis and immune functions Clin Immunol & Immunopathol. 85:1997;120.
5. Yamazaki K., Allen T.D. Ultrastructural morphometric study of efferent nerve terminal on murine bone marrow stromal cells, and the recognition of a novel anatomical unit. The "Neuro-Reticular Complex." Am J Anat. 187:1990;261.
6. Calvo W. The innervation of the bone marrow in laboratory animals. Am J Anat. 123:1986;315.
7. Weihe E., Nohr S., Michel S.et al. Molecular anatomy of the neuro-immune connection. Int J Neurosci. 59:1991;1.
8. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal peptide (VIP) in immunomodulation. Adv Neuroimmunol. 6:1996;5.
9. Bjurholm A., Kreicbergs A., Terenius L., Goldstein M., Schultzberg M. Neuropeptide Y-, typrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J Autonomic Nervous Sys. 25:1988;119.
10. 2 distributions in the bone marrow hematopoietic compartment. I. Krogh's model. Biophys J. 81:2001;675.
11. 2 distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J. 81:2001;685.
12. Leceta J., Martinez C., Delgado M., Garrido E., Gomariz R.P. Expression of vasoactive intestinal peptide in lymphocytes. a possible endogenous role in the regulation of the immune response Adv Neuroimmunol. 6:1996;29.
13. Martinez C., Delgado M., Abad C., Gomariz R.P., Ganea D., Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol. 93:1999;126.
14. Delgado M., Ganea D. Cutting edge. Is vasoactive intestinal peptide a type 2 cytokine? J Immunol. 166:2001;2907.
15. Gomariz R.P., Martinez C., Abad C., Leceta J., Delgado M. Immunology of VIP. a review and therapeutical perspectives Curr Pharm Des. 7:2001;89.
16. Delgado M., Ganea D. VIP and PACAP inhibit NFκB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem. 276:2001;369.
17. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors. actions on the anterior pituitary gland Endocr Rev. 17:1996;4.
18. Harmar A.J., Arimura A., Gozes I.et al. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Pharmacol Rev. 50:1998;265.
19. Calvo J.R., Pozo D., Guerrero J.M. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv Neuroimmunol. 6:1996;39.
20. Usdin T., Bonner T.I., Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 135:1994;2662.
21. Delgado M., Martinez C., Leceta J., Garrido E., Gomariz R.P. Differential VIP and VIP1 gene expression in rat thymocyte subsets. Peptides. 17:1996;803.
22. Delgado M., Munoz-Elias E., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitrix oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J Immunol. 162:1999;4685.
23. Delgado M., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit IL-12 transcription by regulating NFκB and Ets activation. J Biol Chem. 274:1999;31930.
24. Lara-Marquez M.L., O'Dorisio M.S., O'Dorisio T.M., Shah M.H., Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol. 166:2001;2522.
25. Parks S.K., Olson T.A., Ercal N., Summers M., O'Dorisio M.S. Characterization of vasocative intestinal peptide receptors on human megakaryocytes and platelets. Blood. 87:1996;4629.
26. Ganea D., Delgado M. Inhibitory neuropeptide receptors on macrophages. Microbes Infect. 3:2001;141.
27. Ganea D., Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med. 13:2002;229.
28. Delgado M., Abad C., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Med. 7:2001;563.
29. Marie J.-C., Wakkach A., Coudray A.-M., Chastre E., Berrih-Aknin S., Gespach C. Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients. J Immunol. 162:1999;2103.
30. Voice J.K., Dorsam G., Lee H., Kong Y., Goetzl E.J. Allergic diathesis in transgenic mice with constitutive T-cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15:2001;2489.
31. Reubi J.C., Horisberger U., Kappeler A., Laissue J.A. Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. Blood. 92:1998;191.
32. Turtzo L.C., Marx R., Lane M.D. Cross-talk between sympathetic neurons and adipocytes in coculture. Proc Natl Acad Sci U S A. 98:2001;12385.
33. Van Hagen P.M., Krenning E.P., Kwekkeboom D.J.et al. Somatostatin and the immune and haematopoetic system; a review. Eur J Clin Invest. 24:1994;91.
34. Fernandez S., Knopf M.A., McGillis J.P. Calcitonin-gene related peptide (CGRP) inhibits interleukin-7-induced pre-B cell colony formation. J Leukoc Biol. 67:2000;669.
35. Wong H.C., Lloyd S.K., De Giorgio R., Walsh J.H. Monoclonal antibody to VIP. Production, characterization, immunoneutralizing activity, and usefulness in cytochemical staining Hybridoma. 15:1996;133.
36. Rameshwar P., Narayanan R., Qian J., Denny T.N., Colon C., Gascon P. NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis. An inflammatory response beyond the realm of homeostasis J Immunol. 165:2000;2271.
37. Singh D., Joshi D.D., Hameed M.et al. Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells. Implications for bone marrow metastasis. Proc Natl Acad Sci U S A. 97:2000;388.
38. Rameshwar P., Zhu G., Donnelly R.J.et al. The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P. An understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell J Neuroimmunol. 121:2001;22.
39. Rameshwar P., Denny T.N., Gascón P. Enhanced HIV-1 activity in bone marrow can lead to myelopoietic suppression partially contributed by gag p24. J Immunol. 157:1996;4244.
40. Joshi D.D., Dang A., Yadav P.et al. Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P. A combined functional and proteomic study Blood. 98:2001;2697.
41. Muller-Sieburg C.E., Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells. 13:1995;477.
42. Fortunel N.O., Hatzfeld A., Hatzfeld J.A. Transforming growth factor-β pleiotropic role in the regulation of hematopoiesis Blood. 96:2000;2022.
43. + cells purified from cord blood and fetal liver. Exp Hematol. 23:1995;422.
44. Kimata H., Yoshida A., Ishioka C., Fujimoto M., Furusho K. Vasoactive intestinal peptide enhances immunoglobulin production and growth in human plasma cells via mechanisms that may involve protein kinase C. J Clin Endocrinol Metab. 81:1996;3024.
45. Sun W., Tadmori I., Yang L., Delgado M., Ganea D. Vasoactive intestinal peptide (VIP) inhibits TGF-β1 production in murine macrophages. J Neuroimmunol. 107:2000;88.
46. Ganea D., Delgado M. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. Archivum Immunologiae et Therapiae Experimentalis. 49:2001;101.
47. Goetzl E.J., Voice J.K., Shen S.B.et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A. 98:2001;13854.
48. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol. 68:1996;27.
49. Sreedharan S.P., Huang J.-X., Cheung M.H., Goetzl E.J. Structure, expression, and chromosomal localization of the type 1 human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A. 92:1995;2939.
50. Schimozato T., Kincade P.W. Protaglandin E(2) and stem cell factor can deliver opposing signals to B lymphocyte precursors. Cell Immunol. 198:1999;21.
51. O'Reilly M., Gamelli R.L. Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment. Exp Hematol. 18:1990;974.
52. Kim W.K., Kan Y., Ganea D., Hart R.P., Gozes I., Jonakait G.M. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-α production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J Neurosci. 20:2000;3622.
53. Dickinson T., Fleetwood-Walker S.M. Vip and pacap. very important in ? TIPS. 20:1999;324.